drugset / Trial / NCT04683159

Brimonidine Tartrate for Pterygium Surgery

NCT04683159

Unknown 66 enrolled Uptown Eye Specialists
RandomizedParallel-groupTriple-blindPrevention

Summary

Pterygium excision and conjunctival autograft surgery is commonly done to treat pterygiums. Excessive bleeding during the procedure creates a challenging operating field, prolongs surgery time, and prolongs healing. Brimonidine tartrate has a vasoconstrictive effect, which helps to reduce the amount of blood flow and hyperemia to the eye. Preoperative use of brimonidine has been shown to decrease subconjunctival hemorrhage during procedures such as cataract surgery, laser assisted in situ keratomileusis, strabismus surgery, and intravitreal injections. The focus of this study is to assess the effect of preoperative application of brimonidine tartrate 0.15% (Alphagan) and 0.025% (Lumify) on reducing hemorrhage during pterygium excision and conjunctival autograft surgery.

Timeline

Start
2021-02
Primary completion
2021-07
Completion
2021-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Brimonidine Small molecule 0.025 % Topical
Subject Brimonidine Small molecule 0.15 % Topical

Indications